1

Early antiparasitic treatment prevents progression of Chagas disease: Results of a long-term cardiological follow-up study in a pediatric population

Authors: Nicolás González ¹, Samanta Moroni ¹, Guillermo Moscatelli ^{1, 2}, Griselda Ballering ¹, Laura Jurado ^{1, 2}, Nicolás Falk ¹, Andrés Bochoeyer ³, Alejandro Goldsman ³, María Grippo ³, Héctor Freilij ¹, Eric Chatelain ⁴, Jaime Altcheh ^{1, 2 *}.

Affiliations:

¹ Servicio de Parasitología y Chagas, Hospital de Niños Ricardo Gutiérrez, Buenos Aires, Argentina.

² Instituto Multidisciplinario de Investigación en Patologías Pediátricas (IMIPP) (CONICET-GCBA), Buenos Aires, Argentina.

³ Servicio de Cardiología, Hospital de Niños Ricardo Gutiérrez, Buenos Aires, Argentina.

⁴ Drugs for Neglected Diseases *initiative* (DNDi), Geneva, Switzerland.

* Corresponding Author

Keywords: *Trypanosoma cruzi*, cardiological outcome, children, follow-up

Address correspondence to: Nicolás González (ng211@hotmail.com)

Abbreviations: Bz, benznidazole; CD, Chagas disease; cRBBB, complete right bundle branch block; ECG, electrocardiogram; Nf, nifurtimox; STE, speckle-tracking 2D echocardiogram;

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract

Background

Chagas disease (CD), a parasitic disease caused by *Trypanosoma cruzi*. Parasite persistence is crucial in the development and progression of Chagas cardiomyopathy that occurs in 30% of untreated patients.

Methods and findings

A cohort of 95 CD treated children, with at least 6 years post-treatment follow up, was evaluated. Median after treatment follow-up was 10 years. At the time of the last visit a group of non infected subjects were also included as a control for cardiological studies.

During follow-up, the majority of treated subjects 59/61 (96%) achieved negative parasitemia by qPCR at the end of treatment. A decrease in *T. cruzi* antibodies titers were observed and seroconversion by two conventional serology tests (IHA, ELISA) occurred in 53/95 (56%).

Holter showed alterations in 3/95 (3%) of treated patients: isolated ventricular extrasystoles and nocturnal sinus bradycardia (one patient); asymptomatic and vagal related 1st and 2nd degree AV block (one patient); and complete right bundle branch block (cRBBB) (one patient). Only the last one is probably related to CD involvement. 2D speckle tracking echocardiography was conducted in 79/95 (83%) patients and no alterations in myocardial contractility were observed.

In the non infected group Holter evaluations showed similar non pathological results in 3/28 (10%) of subjects: isolated ventricular premature beats (2 patients); asymptomatic 2nd degree AV block with Wenckebach sequences during night time (one patient). 2D speckle tracking echocardiography was conducted in 25/28 (89%) with no alterations.

Conclusions

After long term follow-up of a cohort of treated children for CD, a good parasitocidal treatment effect and a low incidence of cardiological lesions, related to Chagas disease, were observed. These results suggest a protective effect of treatment on the development of cardiological lesions and strengthen the recommendation of early diagnosis and treatment of infected children.

Trial registration

3

59 ClinicalTrials.gov NCT04090489.

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89 Author summary

90 If left untreated, CD evolves into a chronic oligosymptomatic infection that can progress to cardiac
91 complications in 30% of patients after several years.

92 It is known that the main early marker of cardiac involvement are alterations in the conduction system. There
93 are few studies of long-term after treatment cardiological evolution which have assessed the clinical
94 effectiveness of treatment.

95 The rationale for CD treatment is to avoid the development of cardiological complications. The parasitocidal
96 effect of treatment has been demonstrated but its clinical effectiveness in preventing cardiac involvement
97 requires long term follow-up.

98 In our long term follow-up study of treated children, we observed the preventive effect on cardiac lesions by
99 treatment with benznidazole or nifurtimox. This intensifies the need for early diagnosis and treatment to prevent
100 the development of long term complications observed in CD.

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

Introduction

Chagas disease (CD), caused by *Trypanosoma cruzi* (*T. cruzi*), has a broad range of hosts, and is primarily transmitted through infected triatominae bugs or congenitally. [1] Historically considered a regional disease, CD has now become a global phenomenon due to migration, reaching regions such as Europe, USA, Australia and Japan. [2-5]

CD presents with an acute phase with high parasitaemia that, if left untreated, evolves into a chronic oligosymptomatic infection that can progress in 30% [6] of patients to cardiac and/or gastrointestinal complications after several years.

Electrocardiogram (ECG) alterations are early signs of cardiac involvement. Some ECG hallmarks of CD are cRBBB, QRS complex widening or fragmentation, and sinus bradycardia. In more advanced stages, direct damage to the cardiac conduction system is revealed by severe cardiac alterations such as second and third-degree AV block, atrial arrhythmias, ventricular premature beats or ventricular tachycardia. [6-7]

Myocardial deformation imaging is a new technique for quantitative assessment of myocardial contractility. The novel method of speckle-tracking 2D echocardiogram (STE) for myocardial strain imaging can quantitatively assess myocardial contractility deformation, and has been validated for the detection of subclinical left ventricular dysfunction as an early marker of cardiac compromise in CD patients [8]. STE can play an important role in the evaluation of CD patients, especially in the early chronic stage when segmental ventricular wall motion abnormalities are more subtle.

Parasite persistence is crucial to the development and progression of CD cardiomyopathy [9]. Effective antiparasitic treatment of CD could, therefore, prevent complications related to the disease by eliminating tissue parasites. However, there is insufficient data about the impact of medication on the prevention of cardiac lesions, since this requires long-term follow-up of treated patients.

The aim of this study is to describe the incidence of cardiological alterations, the kinetics of *T. cruzi* antibodies and treatment response using *T. cruzi* - PCR after long-term follow-up of a cohort of treated CD children.

Methods and materials

A prospective cohort study of pediatric CD patients treated with benznidazole (Bz) or nifurtimox (Nf) with long-term follow-up was conducted at the Servicio de Parasitología y Chagas, Hospital de Niños Ricardo Gutiérrez, a tertiary referral center in Buenos Aires, Argentina. Children with at least 6 years post-treatment follow-up and

6

who attended a clinical visit between August 2015 and November 2019 were considered for participation in the study.

In order to evaluate the prevalence of normal ECG findings in a group with similar ethnic and socioeconomic characteristics, family members of the same age as treated cases, but without CD, were enrolled as cardiological controls.

Inclusion criteria

- Children with CD treated with Bz or Nf with at least 6 years of post-treatment follow-up.

In infants younger than 8 months CD was diagnosed by direct observation of *T. cruzi* using a parasitological concentration method (microhematocrit test - MH) or xenodiagnosis, and in infants older than 9 months, by two reactive serological tests (ELISA, and indirect hemagglutination - IHA).

- Signed informed consent or assent according to patient age.

Exclusion criteria

- Patients with chronic diseases (renal, hepatic, neurological) that could affect the interpretation of the results (at the discretion of the researcher).

- Subjects with congenital heart disease.

Treatment

Bz (5-8 mg/kg in 2 or 3 doses) and/or Nf (10-12 mg/kg in 2 or 3 doses) was prescribed for 60-90 days. Medication was provided in monthly batches and compliance was assessed by counting the remaining tablets at each visit.

T. cruzi serology and qPCR

Blood samples were collected at diagnosis, end-of-treatment and every 6-12 months after thereafter. Detection of *T. cruzi*-DNA by PCR was carried out in blood (2 mL) mixed with EDTA-guanidine buffer. [10] Serology tests were performed by IHA and ELISA.

Cardiological evaluation

7

ECG was performed at diagnosis and every year following treatment. In addition, cardiological evaluation using 24-hour Holter monitoring and STE were performed at the time of the final study follow-up visit. Cardiological studies were carried out at the Cardiology service of the Hospital de Niños Ricardo Gutiérrez, Buenos Aires, Argentina by trained pediatric cardiologists and pediatric electrophysiologists.

Ethics

The study was approved by the ethics committee of the Hospital de Niños Ricardo Gutiérrez, Buenos Aires, Argentina.

Written informed consent by the patient and healthy controls and/or parents was obtained for all patients according to age and local regulations.

The protocol was registered with ClinicalTrials.gov, NCT04090489.

Statistical analysis

Continuous variables are presented as means with CI_{95%} or medians and interquartile range, and categorical variables as percentages.

The disappearance kinetics of *T. cruzi* serum antibodies were analyzed using survival analysis. Analyses were performed with R software v3.0 (R Core Team 2018, R Foundation for Statistical Computing, Vienna, Austria <https://www.R-project.org/>).

Results

A total of 95 patients (40 male, 55 female) previously treated for CD were enrolled, as well as 28 uninfected children as matched controls for the ECG evaluation (Fig 1). In CD patients, the median age at diagnosis was 4.28 years (range 10 days -20 years); median age at final evaluation was 15 years (range 6-33 years). Subjects were all born in Argentina, and mainly infected through congenital transmission. Following treatment with Bz or Nf, all enrolled subjects continued to reside in Buenos Aires or the Greater Buenos Aires area, where there is no vector transmission that could cause reinfection.

Fig 1. Flow chart of patient enrollment in the study.

The median age of the non-infected control group was 13.2 years (range 6-25 years). These subjects were family members of the infected cases.

The parasitocidal treatments prescribed were Bz in 87 patients and Nf in 8 patients. In 6 cases, treatment was prescribed more than once (see below). Based on tablet counts and medication log reviews, good compliance both for Bz and Nf treatment appears to have been achieved.

Mean Bz dose was 6.5 mg/kg per day (range 5–9.2 mg/day) divided in two (n=84) or three doses (n=3). In 3 cases, data on daily frequency intake were not available. Mean treatment length was 59.8 days (30–60). A total of 80/87 (91.9%) enrolled patients completed drug treatment as prescribed. Bz was well tolerated and adverse drug reactions (ADRs) were mild, requiring treatment suspension in only 4 (4.5%) patients. Of the three remaining patients, two received 30 and 38 days of treatment respectively, while the third received a new cycle of treatment (see below).

Mean Nf dose was 10.8 mg/kg per day (range 5.7–13.9 mg/kg/day) divided in two (n=7) or 3 doses (n=1). Median treatment length was 69.5 days (55–90). All enrolled patients completed drug treatment as prescribed. Nf was well tolerated and ADRs were mild, not requiring treatment suspension.

Six patients received more than one course of treatment: one patient underwent treatment with Bz and, due to difficulties in adherence, a second course of Bz was administered to complete 60 days. Two patients completed their course of treatment with Bz (at the age of 3 and 6 years, respectively), but due to persistently positive qPCRs after treatment, they were considered as treatment failures, and a new course of treatment was indicated; in one case, treatment failure was attributed to a lack of compliance with Bz treatment and so a new course of Bz was prescribed. For the second patient, where there was evidence of good compliance to Bz, the outcome was assumed to be true treatment failure and a course of Nf was prescribed. Both patients showed good treatment compliance and tolerance, and good treatment response with a consistent decrease in *T. cruzi* antibodies and negative qPCR after treatment. In three patients, Bz treatment was suspended due to skin adverse events and all of them subsequently received a new course of treatment with Nf. All three patients showed good tolerance and good treatment response.

Baseline parasitemia data were available for 65 patients: 61 (93%) were initially positive (46 by qPCR, 6 by both qPCR and MH, 7 by MH and 2 by xenodiagnosis). The majority of treated subjects 59/61 (96%) achieved negative parasitemia by *T. cruzi*-qPCR at the end of treatment and remained negative throughout the follow-up period.

In two cases, qPCR results remained positive after treatment; these two patients were considered as treatment failures and a new course of treatment was prescribed, with good response (see above). Reduction in *T. cruzi* antibody titers assessed by conventional serology (IHA and ELISA) was observed during after treatment follow-up in all treated patients. IHA tests became negative in 72/95 (76%) at a median time of 3.17 years (95%CI: 2.38 - 5.76) and ELISA tests became negative in 57/95 (60%) of patients at a median time of 4.68 years (95%CI: 2.87 - 14.50). In 53/95 (56%) both serological tests became negative at a median time of 6 years (95%CI: 4,6 - infinity) (Fig 2).

Fig 2. Serological seroconversion by ELISA and IHA profile in treated patients (Kaplan-Meier).

Cardiological evaluation

24 hour Holter monitoring and STE studies were conducted in both groups, treated patients and non-infected controls. In the treated group, evaluation by Holter was carried out at a median of 10 years after treatment (range 6 - 27 years). This evaluation showed findings in 3/95 (3%) of treated patients (Table 1), including isolated ventricular extrasystoles and nocturnal sinus bradycardia (one patient); asymptomatic and vagal related 1st and 2nd degree AV block (one patient); and cRBBB (one patient). STE was conducted in 79/95 (83%) of patients, including the subjects with Holter alterations. No alterations in myocardial contractility were observed in any patients.

Treated patients group							
Patient ID	Age at treatment (yrs)	Age at evaluation (yrs)	Treatment	Serology at evaluation	STE	Holter finding	Related to CD
ID 24	11	22	Bz 60 days Good compliance	ELISA: Reactive 3.3 IHA: Negative	Normal	Isolated ventricular extrasystoles and nocturnal sinus bradycardia	No
ID 41	1	11	Bz 60 days Good compliance	Negative	Normal	Asymptomatic and vagal related 1st and 2nd degree AV block	No
ID 70	3	19	Bz 70 days Good compliance	Negative	Normal	Complete right bundle branch block	Probable

Non- infected matched control Group			
Patient ID	Age at evaluation (yrs)	STE	Holter finding
ID 8	13	Normal	Asymptomatic 2nd degree AV block with Wenckebach sequences during the night
ID 18	10	Normal	Isolated ventricular premature beats
ID 27	9	Normal	Isolated ventricular premature beats

256

257 In the non-infected group, Holter evaluations yielded similar results to those in the treated group; 3/28 (10%)
258 of subjects had non-specific ECG findings (Table 1), including isolated ventricular premature beats in 2 patients
259 and asymptomatic 2nd degree AV block with Wenckebach sequences during the night in one patient. STE
260 was conducted in 25/28 (89%) of patients and no alterations in myocardial contractility were observed in any
261 of the cases evaluated.

262

263 Discussion

264 Currently, CD treatment with Bz or Nf is recommended as the standard of care for acute and early chronic
265 phases in children. In the early phase of infection, which is more easily observed in children, the majority of
266 cases are asymptomatic and without cardiac involvement, as described in this study. However, approximately
267 30% of untreated patients with CD will eventually develop cardiomyopathy in the chronic stage. [7, 11]

268 Multiple mechanisms may be responsible for the development of cardiac lesions in T. cruzi infection. The
269 presence and persistence of the parasite is a critical factor which triggers a specific immune response, inducing
270 vascular endothelial cell damage. This may play an important role in the pathogenesis of CD cardiac
271 involvement. [12]

272 At tissue level, a diffuse cellular infiltrate with microcirculation alterations affects the parasympathetic
273 innervations, increasing sympathetic activity, and leading to further cardiac damage and development of
274 arrhythmia. [13]

275 The treatment of infected subjects is, therefore, based on the elimination of intracellular parasites to avoid the
276 development of future cardiological complications.

277 In previous studies [14], we described the effectiveness of parasitocidal treatment in children. There was a
278 decrease in T.cruzi antibodies measured by conventional serology and persistent non-detection of T.cruzi-
279 qPCR during after-treatment follow-up. The parasitocidal effect of Bz and Nf was demonstrated by the
280 clearance of parasitemia.

281 Electrocardiographic abnormalities are often the first indicator of CD cardiac involvement. The earliest ECG
282 abnormalities of Chagas cardiomyopathy usually involve abnormalities of the conduction system, manifesting
283 most frequently as different degrees of sinus dysfunction, right bundle branch block and / or left anterior
284 fascicular block. Second and third degree atrioventricular blocks, as well as ventricular arrhythmias, have also
285 been described in relation to advanced CD lesions.

286 There are few studies that have investigated the clinical effectiveness of CD treatment through the evaluation
 287 of cardiological events by long-term follow-up of asymptomatic treated children. It is important to note that
 288 children are different from adults. Although the basic principles of cardiac conduction and depolarization are
 289 the same as for adults, age-related changes in the anatomy and physiology of infants and children produce
 290 normal ranges for electrocardiographic features that differ from adults and vary with age. Conduction intervals
 291 (PR interval, QRS duration) are shorter than adults due to smaller cardiac size. First degree AV block and
 292 Wenckebach sequence may be a normal finding in healthy children during rest or under vagal tone. The QT
 293 interval depends on heart rate and age. Heart rates are much faster in neonates and infants, decreasing as
 294 the child grows older. Thus, cardiological evaluation in children must be conducted by pediatric cardiologists
 295 since features that would be diagnosed as abnormal in adult's ECG may be normal, age-related findings in a
 296 pediatric ECG trace. This can be explained by the way the heart develops during infancy and childhood. The
 297 right ventricular dominance of the neonate and infant is gradually replaced by left ventricular dominance so
 298 that by 3-4 years the pediatric ECG resembles that of adults. In addition, some pathological findings could be
 299 related to technical issues and in other cases may be related to congenital lesions and not produced by T.
 300 cruzi infection. Awareness of these differences is the key to correct interpretation of pediatric
 301 electrocardiograms. [15]

302 In non-treated CD patients, the overall reported rate of cardiac disease progression is between 13 and 25 %
 303 [16] with a 2 to 4 % annual progression rate. [17] In our cohort, the median after-treatment follow-up time was
 304 10 years (6.02 - 26.9) and only one patient showed ECG alterations that could possibly be related to T. cruzi
 305 infection. The other ECG findings observed (which could be considered abnormal from an adult ECG
 306 perspective) were in fact likely to be normal ECG findings in our pediatric cohort of patients, and therefore
 307 unrelated to CD, with only one patient showing signs compatible with cardiac involvement in CD (i.e. complete
 308 right bundle branch block) [7]. The other two patients with Holter findings showed non-specific ECG alterations
 309 that are currently considered normal variations. To correct for the limited amount of data in healthy populations
 310 with similar ethnic and socioeconomic characteristics as our patients, we enrolled a non-infected group of
 311 volunteers as a control group in order to better establish a "normal" baseline for the Holter evaluation. Notably,
 312 no differences in the prevalence of ECG normal variations were found between the treated and uninfected
 313 groups.

314 Several published studies which reported ECG abnormalities in children with CD showed alterations that are
 315 unlikely to be related to CD, and in many cases should simply be considered as normal variants for age. [18-

20] In a 3-year follow-up of treated children in the chronic phase, it was shown that only one child in the Bz group and four in the control group developed complete right bundle branch block (p: 0.36). At the 6-year follow-up time-point, no progression of cardiac lesions was observed.

In another study, 18.6% of treated children showed ECG changes during follow-up. Only four children presented alterations of right bundle conduction that could be attributed to CD but which were not pathognomonic lesions due to CD. The risk of incidence of ECG alterations comparing treated versus untreated children was 0.74 (95% CI: 0.28 -1.97, p: 0.54), showing no differences between the group. [21] This study suggested that the treatment did not stop the appearance of new cardiac lesions. However, the anomalies described were mostly normal findings characteristic in children (i.e. extrasystoles, incomplete right bundle branch block, first-degree atrioventricular block) and unlikely to be related to CD.

Several observational studies in adults have shown the positive effect of treatment on the prevention of the development of cardiac alterations. [22-25]

In contrast, in the BENEFIT study [26] no difference between treated adult subjects and the placebo group was observed. However, this was a different population in which severe cardiac pathology was already present and by this stage the cardiological damage was probably irreversible and not modifiable by the parasitocidal treatment.

In our study, all evaluated patients showed normal myocardial contractility as measured by STE. Over the last few years echocardiography has become the most common imaging modality used to assess and follow-up patients with CD. In the early stages of cardiac involvement, ventricular wall motion abnormalities are observed, and STE allows a more precise measurement of regional myocardial function. [8]

The results of the current study confirmed the efficacy and safety of Bz and Nf in pediatric CD patients. In addition, we did not find a higher incidence of ECG alterations in patients treated in childhood for CD with a long-term after-treatment follow-up, which could be related to a protective effect of treatment at an early stage of T. cruzi infection.

Presently, the standard of care for CD is the universal treatment of all infected children. The results of this study support early screening for T. cruzi infection in children and infants from infected mothers so that timely treatment can be provided. Early diagnosis and treatment could prevent or slow the progression of cardiac involvement in chronic CD.

We concluded that all treated patients showed parasitological and serological signs of treatment response (seroreversion in more than half of the patients, constant negative qPCR and a decrease in antibodies titers

for the others). More importantly, we have shown that the development of cardiac alterations was prevented by parasitocidal treatment after a median follow-up of over a decade, apart from one patient who showed signs of potential cardiac pathology related to CD. These results further underline the importance of early diagnosis and availability of treatment, especially for children, young adults and women of childbearing age, in order to prevent new infections and development of symptomatic chronic Chagas disease. Further studies with long-term follow-up (20-30 years) of the present cohort will be conducted in order to confirm that early treatment prevents later cardiological compromise in CD patients.

References

1. Altcheh JM, Freilij H. Chagas Disease: A Clinical Approach. Springer Nature; 2019. 356 p.
2. Schmunis GA. Epidemiology of Chagas disease in non-endemic countries: the role of international migration. Mem Inst Oswaldo Cruz. 2007 Oct 30;102 Suppl 1:75–85.
3. Basile L, Jansa JM, Carlier Y, Salamanca DD, Angheben A, Bartoloni A, et al. Chagas disease in European countries: the challenge of a surveillance system. Euro Surveill [Internet]. 2011 Sep 15;16(37). Available from: <https://www.ncbi.nlm.nih.gov/pubmed/21944556>
4. Moscatelli G, García Bournissen F, Freilij H, Berenstein A, Tarlovsky A, Moroni S, et al. Impact of migration on the occurrence of new cases of Chagas disease in Buenos Aires city, Argentina. J Infect Dev Ctries. 2013 Aug 15;7(8):635–7.
5. Montgomery SP, Starr MC, Cantey PT, Edwards MS, Meymandi SK. Neglected parasitic infections in the United States: Chagas disease. Am J Trop Med Hyg. 2014 May;90(5):814–8.
6. Prata A. Clinical and epidemiological aspects of Chagas disease. Lancet Infect Dis. 2001 Sep;1(2):92–100.
7. Rojas LZ, Glisic M, Pletsch-Borba L, Echeverría LE, Bramer WM, Bano A, et al. Electrocardiographic abnormalities in Chagas disease in the general population: A systematic review and meta-analysis. PLoS Negl Trop Dis. 2018 Jun;12(6):e0006567.
8. Acquatella H, Asch FM, Barbosa MM, Barros M, Bern C, Cavalcante JL, et al. Recommendations for Multimodality Cardiac Imaging in Patients with Chagas Disease: A Report from the American Society of Echocardiography in Collaboration With the InterAmerican Association of Echocardiography (ECOSIAC) and the Cardiovascular Imaging Department of the Brazilian Society of Cardiology (DIC-SBC). J Am Soc Echocardiogr. 2018 Jan;31(1):3–25.
9. Zhang L, Tarleton RL. Parasite persistence correlates with disease severity and localization in chronic Chagas' disease. J Infect Dis. 1999 Aug;180(2):480–6.
10. Duffy T, Bisio M, Altcheh J, Burgos JM, Diez M, Levin MJ, et al. Accurate real-time PCR strategy for monitoring bloodstream parasitic loads in chagas disease patients. PLoS Negl Trop Dis. 2009 Apr

398 21;3(4):e419.

399 11. Rassi A Jr, Rassi A, Little WC, Xavier SS, Rassi SG, Rassi AG, et al. Development and validation of a
400 risk score for predicting death in Chagas' heart disease. N Engl J Med. 2006 Aug 24;355(8):799–808.

401 12. Dávila DF, Rossell O, de Bellabarba GA. Pathogenesis of chronic chagas heart disease: parasite
402 persistence and autoimmune responses versus cardiac remodelling and neurohormonal activation. Int J
403 Parasitol. 2002 Jan;32(1):107–9.

404 13. Bonney KM, Engman DM. Chagas heart disease pathogenesis: one mechanism or many? Curr Mol
405 Med. 2008 Sep;8(6):510–8.

406 14. Moscatelli G, Moroni S, García Bournissen F, González N, Ballering G, Schijman A, et al. Longitudinal
407 follow up of serological response in children treated for Chagas disease. PLoS Negl Trop Dis. 2019
408 Aug;13(8):e0007668.

409 15. Goodacre S, McLeod K. ABC of clinical electrocardiography: Paediatric electrocardiography. BMJ. 2002
410 Jun 8;324(7350):1382–5.

411 16. Pinto Dias JC. [Natural history of Chagas disease]. Arq Bras Cardiol. 1995 Oct;65(4):359–66.

412 17. Maguire JH, Hoff R, Sherlock I, Guimarães AC, Sleigh AC, Ramos NB, et al. Cardiac morbidity and
413 mortality due to Chagas' disease: prospective electrocardiographic study of a Brazilian community.
414 Circulation. 1987 Jun;75(6):1140–5.

415 18. Bianchi F, Cucunubá Z, Guhl F, González NL, Freilij H, Nicholls RS, et al. Follow-up of an asymptomatic
416 Chagas disease population of children after treatment with nifurtimox (Lampit) in a sylvatic endemic
417 transmission area of Colombia. PLoS Negl Trop Dis. 2015 Feb;9(2):e0003465.

418 19. Rangel-Flores H, Sánchez B, Mendoza-Duarte J, Barnabé C, Brenière FS, Ramos C, et al. Serologic
419 and parasitologic demonstration of Trypanosoma cruzi infections in an urban area of central Mexico:
420 correlation with electrocardiographic alterations. Am J Trop Med Hyg. 2001 Dec;65(6):887–95.

421 20. de Andrade AL, Zicker F, Rassi A, Rassi AG, Oliveira RM, Silva SA, et al. Early electrocardiographic
422 abnormalities in Trypanosoma cruzi-seropositive children. Am J Trop Med Hyg. 1998 Oct;59(4):530–4.

423 21. Colantonio LD, Prado N, Segura EL, Sosa-Estani S. Electrocardiographic Abnormalities and Treatment

- 424 with Benznidazole among Children with Chronic Infection by Trypanosoma cruzi: A Retrospective
425 Cohort Study. PLoS Negl Trop Dis. 2016 May;10(5):e0004651.
- 426 22. Viotti R, Vigliano C, Lococo B, Bertocchi G, Petti M, Alvarez MG, et al. Long-term cardiac outcomes of
427 treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann
428 Intern Med. 2006 May 16;144(10):724–34.
- 429 23. Fabbro DL, Streiger ML, Arias ED, Bizai ML, del Barco M, Amicone NA. Trypanocide treatment among
430 adults with chronic Chagas disease living in Santa Fe city (Argentina), over a mean follow-up of 21
431 years: parasitological, serological and clinical evolution. Rev Soc Bras Med Trop. 2007 Jan;40(1):1–10.
- 432 24. Machado-de-Assis GF, Diniz GA, Montoya RA, Dias JCP, Coura JR, Machado-Coelho GLL, et al. A
433 serological, parasitological and clinical evaluation of untreated Chagas disease patients and those
434 treated with benznidazole before and thirteen years after intervention. Mem Inst Oswaldo Cruz. 2013
435 Nov;108(7):873–80.
- 436 25. Fragata-Filho AA, França FF, Fragata C da S, Lourenço AM, Faccini CC, Costa CA de J. Evaluation of
437 Parasiticide Treatment with Benznidazol in the Electrocardiographic, Clinical, and Serological Evolution
438 of Chagas Disease. PLoS Negl Trop Dis. 2016 Mar;10(3):e0004508.
- 439 26. Morillo CA, Marin-Neto JA, Avezum A, Sosa-Estani S, Rassi A Jr, Rosas F, et al. Randomized Trial of
440 Benznidazole for Chronic Chagas' Cardiomyopathy. N Engl J Med. 2015 Oct;373(14):1295–306.

441

442 **Supporting information**

443 **S1 File. STROBE Statement.** Checklist of items that should be included in reports of cohort studies.

Enrolled
n = 123

Treated group
n = 95

Bz: n= 87 (91,6%);
Nf: n= 8 (8,4%)

Control group
n = 28

Median follow-up
time: 10.8 yrs
Seroconversion:
n= 53 (56%)
Negative parasitemia:
n= 61/61 (100%)

ECG findings
n = 3/95 (3%)

ECG findings
related to CD
n = 1/95
(0,9%)

ECG findings
n = 3/28
(10%)

Proportion of patients without seroreversion

Strata Elisa & IHA

Number at risk

Cumulative number of events